Skip to main content
SpringerLink
Log in

Neurological Consequences of Antiretroviral Treatment

  • Chapter
The Neurological Manifestations of Pediatric Infectious Diseases and Immunodeficiency Syndromes

Part of the book series: Infectious Disease™ ((ID))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. 1. Gabuzda DH, Hirsch MS. Neurologic manifestations of infection with human immunodeficiency virus. Clinical features and pathogenesis. Ann Intern Med. 1987; 107:383–391.

    PubMed  CAS  Google Scholar 

  2. Global Report on the AIDS epidemic. UNAIDS. May 2006.

    Google Scholar 

  3. 3. Spudich SS, Huang W, Nilsson AC, Petropoulos CJ. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Inf Dis. 2005; 191:890–898.

    Article  CAS  Google Scholar 

  4. 4. Rabkin JG, Ferrando S. A ‘second life’ agenda. Psychiatric research issues raised by protease inhibitor treatments for people with human immunodeficiency virus or the acquired immunodeficiency syndrome. Arch Gen Psych. 1997; 54:1049–1053.

    CAS  Google Scholar 

  5. 5. Eggers C, Hertogs K, Sturenberg HJ. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration AIDS. 2003; 17:1897–1906.

    Article  PubMed  Google Scholar 

  6. 6. Tamula MA, Wolters PL, Walsek C. Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. Pediatrics. 2003; 112:679–684.

    Article  PubMed  Google Scholar 

  7. 7. Brouwers P, Moss H, Wolters P. Effects of continuous infusion Zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus. J Pediatr. 1990; 117:980–985.

    Article  PubMed  CAS  Google Scholar 

  8. 8. Chiriboga CA, Fleishman S, Champion S, Gaye-Robinson L, Abrams EJ. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). J Pediatr. 2005; 146:402–407.

    Article  PubMed  Google Scholar 

  9. 9. Alimenti A, Burdge DR, Ogolvie GS, et al. Lactic acidemia in human immunodeficiency virus-uninfected infected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J. 2003; 22:782–788.

    Article  PubMed  Google Scholar 

  10. 10. Schweinberg BC, Taylor MJ, Alhassoon OM. Brain mitochondrial injury in human immunodeficiency virus—seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol. 2005; 11:356–364.

    Article  Google Scholar 

  11. 11. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999; 354;1084–1089.

    Article  PubMed  Google Scholar 

  12. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr. 2000; 25:261–268.

    Google Scholar 

  13. 13. Poirier MC, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr. 2003; 33:175–183.

    Article  PubMed  Google Scholar 

  14. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003; 32:380–387.

    Google Scholar 

  15. 15. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005; 38:449–473.

    Article  PubMed  CAS  Google Scholar 

  16. Didanosine, Videx. Bristol Myers Squibb, Product Information. 2006.

    Google Scholar 

  17. Stavudine, Zerit. Bristol Myers Squibb, Product Information. 2006.

    Google Scholar 

  18. 18. Brew B. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Mus Ner. 2003; 28:542–552.

    Article  CAS  Google Scholar 

  19. 19. Osio M, Muscia F, Zampini L, et al. Acetyl-l-carnitine in the treatment of painful antiretroviral neuropathy in human immunodeficiency virus patients: an open label study. J Periph Nerv Sys. 2006; 11:72–76.

    Article  CAS  Google Scholar 

  20. 20. Famularo G, Moretti S, Marcellini S, et al. Acetylcarnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS. 1997; 11:185–190.

    Article  PubMed  CAS  Google Scholar 

  21. Marcus K, Truffa M, Boxwell D. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: cases from the FDA's reporting system (abstract LB14). In: Programs and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle) 2002.

    Google Scholar 

  22. 22. Mitchell W. Neurological and developmental effects of HIV and AIDS in children and adolescents. Ment Retard Dev Disabil Res Rev. 2001; 7:211–216.

    Article  PubMed  CAS  Google Scholar 

  23. 23. Sullivan JL, Luzuriaga K. The changing face of pediatric HIV-1 infection. N Engl J Med. 2001; 345:1568–1569.

    Article  PubMed  CAS  Google Scholar 

  24. 24. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331:1173.

    Article  PubMed  CAS  Google Scholar 

  25. 25. Kumar RM, Hughes PF, Khurranna A. Zidovudine use in pregnancy: a report on 104 cases and the occurrence of birth defects. J Acq Imm Def Synd. 1994; 7:1034.

    CAS  Google Scholar 

  26. Efavirenz, Sustiva. Bristol Myers Squibb, Product Information. 2006.

    Google Scholar 

  27. 27. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynec. 2003; 101:797–810.

    Article  PubMed  Google Scholar 

  28. 28. Watts DH. Management of human immunodeficiency virus in pregnancy. N Engl J Med. 2002; 346:1879–1891.

    Article  PubMed  CAS  Google Scholar 

  29. 29. Gisslen M, Hagberg L. Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med. 2001; 2(2):97–104.

    Article  PubMed  CAS  Google Scholar 

  30. 30. Tamula MA, Wolters PL, Walsek C. Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. Pediatrics. 2003; 112:679–684.

    Article  PubMed  Google Scholar 

  31. 31. DeLuca A, Ciancio B, Larussa D, et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurol. 2002; 59:342–347.

    CAS  Google Scholar 

  32. 32. Cunningham P, Smith D, Satchell C, Cooper D, Brew B. Evidence for independent development of reverse transcriptase inhibitor resistance patterns in the cerebrospinal fluid. AIDS. 2000; 14:1949–1954.

    Article  PubMed  CAS  Google Scholar 

  33. 33. Belman AL. HIV-1 infection and AIDS. Neurol Clin. 2002; 20:983–1011.

    Article  PubMed  Google Scholar 

  34. 34. Cherry CL, McArthur JC, Hoy JF. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol. 2003; 26:195–207.

    Article  PubMed  CAS  Google Scholar 

  35. 35. Brinkman K, ter Hofstede HG, Hadewych JM. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998; 12:1735–1744.

    Article  PubMed  CAS  Google Scholar 

  36. 36. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Therap. 2000; 22:685–708.

    Article  CAS  Google Scholar 

  37. 37. Church JA, Mitchell WG, Gonzalez-Gomez I. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr. 2001; 138:748–751.

    Article  PubMed  CAS  Google Scholar 

  38. 38. Husstedt I, Frohne L, Bockenholt S. Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: cross-sectional and longitudinal studies of event-related potentials. AIDS Res Hum Retro. 2002; 18:485–490.

    Article  CAS  Google Scholar 

  39. 39. Antinouri A, Giancola ML, Grisetti S. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1 infected patients. AIDS. 2002; 16:1867–1876.

    Article  Google Scholar 

  40. 40. Arendt G, Giesen HV, Hefter H. Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection. AIDS. 2001; 15:493–500.

    Article  PubMed  CAS  Google Scholar 

  41. 41. Raskino CR, Pearson DA, Baker CJ. Neurologic, neurocognitive and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatrics. 1999; 104:1–10.

    Article  Google Scholar 

  42. 42. Price RW, Yiannoutsos CT, Clifford DB. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS. 1999; 13:1677–1685.

    Article  PubMed  CAS  Google Scholar 

  43. 43. Rauch DM, Stover ES. Neuroscience research in AIDS. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25:231–257.

    Article  Google Scholar 

  44. 44. Calamandrei G, Valanzano A, Puopolo M. Developmental exposure to the antiretroviral drug zidovudine increases brain levels of brain-derived neurotropic factor in mice. Neuroscience Letters. 2002; 333:111–114.

    Article  PubMed  CAS  Google Scholar 

  45. 45. Treisman GJ, Kaplina AI. Neurologic and psychiatric complications of antiretroviral agents. AIDS. 2002; 16:1201–1215.

    Article  PubMed  CAS  Google Scholar 

  46. 46. Simpson DM, Haidich A, Schitto G, et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS. 2002; 16:407–412.

    Article  PubMed  CAS  Google Scholar 

  47. Keswania SC, Pardoa CA, Cherry CL, et al. HIV-1 associated sensory neuropathies. AIDS. 16:2105–2117.

    Google Scholar 

  48. 48. Geraci AP, Simpson DM. Neurological manifestations of HIV-1 infection in the HAART era. Comp Ther. 2001; 27:232–241.

    Article  CAS  Google Scholar 

  49. 49. Geraci AP, Di Rocco AD, Simpson DM. Neurologic complications of AIDS. Neurologist. 2001; 7:82–97.

    Google Scholar 

  50. 50. Wulff EA, Simpson DM. Neuromuscular complications of the human immunodeficiency virus type 1 infection. Semin Neurol. 1999:19:157–164.

    Article  PubMed  CAS  Google Scholar 

  51. 51. Araujo A, Nascimneto OJ, Garcia OS. Distal sensory polyneuropathy in a cohort of HIV-infected children over five years of age. Pediatrics. 2000; 106:E35.

    Article  PubMed  CAS  Google Scholar 

  52. 52. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clinical Therapeutics. 2000; 22:911–936.

    Article  PubMed  CAS  Google Scholar 

  53. 53. Dalakas M. Peripheral neuropathy and antiretroviral drugs. J Periph Nerv Syst. 2001; 6:14–20.

    Article  CAS  Google Scholar 

  54. Pediatric Antiretroviral Drug Information, DHHS Pediatric Guidelines. 2006.

    Google Scholar 

  55. 55. Reliquet V, Mussini JM, Lafeuillade A. Peripheral neuropathy during stavudine-didanosine antiretroviral therapy. HIV Med. 2001; 2:92–96.

    Article  PubMed  CAS  Google Scholar 

  56. Lamivudine, Epivir. Glaxo Wellcome, Product Information. 2002.

    Google Scholar 

  57. 57. Foster R. Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Med. 2003; 4:139–144.

    Article  PubMed  CAS  Google Scholar 

  58. Abacavir, Ziagen. Glaxo Wellcome, Product Information. 2002.

    Google Scholar 

  59. 59. Colebunders R, Hilbrands R, DeRoo A. Neuropsychiatric reaction induced by abacavir. Am J Med. 2002; 113:616.

    Article  PubMed  Google Scholar 

  60. Tenofovir, Viread. Gilead, Product Information. 2006.

    Google Scholar 

  61. Pharmacokinetics of Viread. Gilead, 2003.

    Google Scholar 

  62. Emtrictabine (FTC, Emtriva). Gilead, Product Information. 2006.

    Google Scholar 

  63. 63. Maddocks S, Dwyer D. The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection. Pediatric Drugs. 2001; 3:681–702.

    Article  PubMed  CAS  Google Scholar 

  64. 64. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs. 2002; 16:595–609.

    Article  PubMed  CAS  Google Scholar 

  65. 65. Glynn SL, Yazanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharma Sci. 1998; 87:306–310.

    Article  CAS  Google Scholar 

  66. 66. Gutierrez F, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005; 41:1648–1653.

    Article  PubMed  CAS  Google Scholar 

  67. 67. Teglas JP, Quartier P, Treluyer JM, et al. Tolerance of efavirenz in children. AIDS. 2001; 15:241–243.

    Article  PubMed  CAS  Google Scholar 

  68. 68. Wise ME. Neuropsychiatric complications of nevirapine treatment. BMJ. 2002; 324:879.

    Article  PubMed  Google Scholar 

  69. 69. Marzolini C, Christoph R, Decosterd LA Transplacental passage of protease inhibitors at delivery. AIDS. 2002; 16:889–893.

    Article  PubMed  CAS  Google Scholar 

  70. 70. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci. 2000; 918:287–297.

    Article  PubMed  CAS  Google Scholar 

  71. 71. Capparelli EV, Holland D, Okamotot C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS. 2005; 19:949–952.

    Article  PubMed  CAS  Google Scholar 

  72. 72. Martin C, Sonnerborg A, Svensson O, et al. Indinavir-based treatment of HIV-1 infected patients; efficacy in the central nervous system. AIDS. 1999; 13:1227–1232.

    Article  PubMed  CAS  Google Scholar 

  73. Tipranvir (Aptivus). Boehringer Ingelheim, Product Information. 2006.

    Google Scholar 

  74. Darunavir (Prezista). Tibotec, Product Information. 2006.

    Google Scholar 

  75. Enfuvirtide, Fuzeon. Roche, Product Information. 2003.

    Google Scholar 

  76. 76. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2002, 21:653–659.

    Article  PubMed  Google Scholar 

  77. Price RW, Palmatier R, Wring S, et al. Enfuvirtide cerebrospinal fluid pharmacokinetics: a potential tool to analyze CSF HIV origin and the therapeutic role of local drug penetration. (abstract 402). In: Programs and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston) 2005.

    Google Scholar 

  78. 78. Piliero P, Fish DG, Preston S, et al. Guillain-Barré syndrome associated with immune reconstitution. Clin Infect Dis. 2003; 36:111–114.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Assistant Professor of Pediatrics, University of Florida College of Medicine, Jacksonville, FL, USA

    Kimberley C. Brown Pharm.D.

  2. University of Florida College of Pharmacy, Jacksonville, FL, USA

    Lisa D. Inge Pharm.D.

  3. Chief Division of Pediatric Infectious Diseases and Immunology, Univer-sity of Florida College of Medicine and Wolfson Children's Hospital, Director Rainbow Center for Women, Adolescents, Children and Families, Jacksonville, FL, USA

    Mobeen H. Rathore M.D., C.P.E., F.A.A.P. (Professor of Pediatrics and Associate Chairman)

Authors
  1. Kimberley C. Brown Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa D. Inge Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mobeen H. Rathore M.D., C.P.E., F.A.A.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science + Business Media, LLC

About this chapter

Cite this chapter

Brown, K.C., Inge, L.D., Rathore, M.H. (2008). Neurological Consequences of Antiretroviral Treatment. In: The Neurological Manifestations of Pediatric Infectious Diseases and Immunodeficiency Syndromes. Infectious Disease™. Humana Press. https://doi.org/10.1007/978-1-59745-391-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-391-2_11

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-967-3

  • Online ISBN: 978-1-59745-391-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation